top of page

2024 ROS1+ Cancer Innovation Award is open for submissions


The ROS1+ Cancer Innovation Award funds high-risk, high-reward research projects focused on ROS1+ cancer. The one-year, $75,000 seed grant can be used for pre-clinical, translational, or clinical research and is open to investigators who hold a doctorate degree and a faculty appointment at an academic or non-profit research institution anywhere in the world.

 

The award uses a two-step application process:

  1. A letter of intent (LOI), with a brief overview of the proposed project and biographical information

  2. A full application with an extended narrative about the project, as well as supporting information and documentation. (Because there are a limited number of awards, only a subset of applicants is invited to submit a full application after the LOI review is completed.)


Reviewers are drawn from The ROS1ders' Scientific Advisory Board and patient research advocate members. 


2023 ROS1+ Cancer Innovation awards were given to two projects, "Novel murine ROS1+ cancer models for next-generation therapeutics" and "An international consortium to generate high-quality real-world evidence for the optimization of treatment strategies in ROS1-positive lung cancer."

 

LOI applications must be submitted online at proposalCENTRAL by May 3, 2024. A complete description, terms and conditions, and instructions are included in the ROS1+ Cancer Innovation Award RFA.

41 views0 comments

Related Posts

See All

Comments


bottom of page